Treating hepatitis C in patients with hemoglobinopathies

Bibliography

• Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med 2012;2:a011692
   PubMed Web of Science ®Google Scholar
• Christofidou M, Lambropoulou-Karatza C, Dimitracopoulos G, Spiliopoulou I. Distribution of hepatitis C genotypes in viremic patients with beta-thalassemia. Eur J Clinic Microbiol Infect Dis 2000;19:728-30
   PubMed Web of Science ®Google Scholar
• Di Marco V, Capra M, Angelucci E, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an International panel. Blood 2010;116:2875-83
   PubMed Web of Science ®Google Scholar
• Hassan M, Hasan S, Castro O, et al. HCV in sickle cell disease. J Natl Med Assoc 2003;95:939-42
   PubMed Web of Science ®Google Scholar
• Issa H. Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. World J Hepatol 2010;2:180-4
   PubMedGoogle Scholar
• Al-Faleh FZ, Ramia S. Hepatitis C virus (HCV) infection in Saudi Arabia: a review. Ann Saudi Med 1997;17:77-82
   Web of Science ®Google Scholar
• Hasan MF, Marsh F, Posner G, et al. Chronic hepatitis C in patients with sickle cell disease. Am J Gastroenterol 1996;91:1204-6
   PubMed Web of Science ®Google Scholar
• De Vault KR, Friedman LS, Westerberg S, et al. Hepatitis C in sickle cell anemia. J Clin Gastroenterology 1994;18:206-9
   PubMed Web of Science ®Google Scholar
• Castro O, Frederick W. Hepatitis-C virus antibodies in sickle cell disease (SCD) patients. Blood 1991;78:477a
   Google Scholar
• Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusions and deferoxamine. Hematologica 2004;89:1187-93
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005;1054:40-7
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Garani MC, Forni GL, et al. Hepatocellular carcinoma in thalassemia: an update of the Italian Registry. Br J Hematol 2014;167:121-6
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Ladis V, Kattamis A, et al. A national registry of hemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol 2012;91:1451-8
   PubMed Web of Science ®Google Scholar
• Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964;30:698-705
   PubMed Web of Science ®Google Scholar
• Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus 2012;10:411-22
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2014. J Hepatol 2014;61:373-95
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63(1):199-236
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
   PubMed Web of Science ®Google Scholar
• Available from: http://www.gazzettaufficiale.it/eli/id/2009/09/08/09A10528/sg
   Google Scholar
• Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Aghemo A, Colombo M. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 2012;12:361-8
   PubMed Web of Science ®Google Scholar
• Klenerman P, Lechner F, Kantzanou M, et al. Viral escape and the failure of cellular immune responses. Science 2000;289:2003
   PubMedGoogle Scholar
• Prati D, Maggioni M, Milani S, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Hematologica 2004;89:1179-86
   PubMed Web of Science ®Google Scholar
• Kushner JP, Porter JB, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;47-61
   PubMedGoogle Scholar
• Available from: http://asheducationbook.hematologylibrary.org/archive/index.dtl [Last accessed 16 July 2015]
   Google Scholar
• Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Hematol 2007;78:487-94
   PubMed Web of Science ®Google Scholar
• Cooley’s anemia foundation. Available from: www.thalassemia.org [Last accessed 17 August 2015]
   Google Scholar
• Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341:1986-95
   PubMed Web of Science ®Google Scholar
• Ardalan FA, Osquei MR, Toosi MN, et al. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol 2004;4:17
   PubMed Web of Science ®Google Scholar
• Brissot P, Turlin B, Forni G-L, et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia. Blood 2005;106:Abstract 823
   Google Scholar
• Deugnier Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011;141:1202-11
   PubMed Web of Science ®Google Scholar
• Di Marco V, Capra M, Gagliardotto F. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Hematologica 2008;92:1243-6
   Web of Science ®Google Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. Blood 2004;104:34-9
   PubMed Web of Science ®Google Scholar
• Perifanis V, Tziomalos K, Tsatra I, et al. Prevalence and severity of liver disease in patients with beta-thalassemia major. A single-institution fifteen-year experience. Hematologica 2005;90:1136-8
   PubMed Web of Science ®Google Scholar
• Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006;30:119-24
   PubMed Web of Science ®Google Scholar
• Mancuso A. Hepatocellular carcinoma in thalassemia: a critical review. World J Hepatol 2010;2:171-4
   PubMedGoogle Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study. Blood 2010;115:1886-92
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naïve patients with thalassemia intermedia. Br J Hematol 2010;150:486-9
   PubMed Web of Science ®Google Scholar
• Maakaron JE, Cappellini MD, Graziadei G, et al. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol 2013;12:142-6
   PubMed Web of Science ®Google Scholar
• Maakaron JE, Musallam KM, Ayache JB, et al. A liver mass in an iron overloaded thalassemia intermedia patient. Br J Hematol 2013;161:1
   PubMed Web of Science ®Google Scholar
• Restivo Pantalone G, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassemia syndromes: clinical characteristics and outcome in a long-term single center experience. Br J Hematol 2010;150:245-7
   PubMed Web of Science ®Google Scholar
• Krauss JS, Freant LJ, Lee JR. Gastrointestinal pathology in sickle cell disease. Ann Clin Lab Sci 1998;28:19-23
   PubMed Web of Science ®Google Scholar
• Shaho SH, Orriger EP. Sickle cell intrahepatic cholestasis; approach to a difficult problem. Am J Gastroenterol 1995;90:2048-50
   PubMed Web of Science ®Google Scholar
• Bauer TW, Moore GW, Hutchins GM. The liver in sickle cell disease. A clinicopathologic study of 70 patients. Am J Med 1980;69:833-7
   PubMed Web of Science ®Google Scholar
• Gurkan E, Ergun J, Zorludemir S, et al. Liver involvement in sickle cell disease. Turk J Gastroenterol 2005;16:194-8
   PubMedGoogle Scholar
• Brissot P, Bourel M, Herry D, et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 1981;80:557-65
   PubMed Web of Science ®Google Scholar
• Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a non-invasive method for the assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13
   PubMed Web of Science ®Google Scholar
• Castera L. Non invasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-302
   PubMed Web of Science ®Google Scholar
• Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73
   PubMed Web of Science ®Google Scholar
• Di Marco V, Bronte F, Cabibi D. Non-invasive assessment of liver fibrosis in thalassemia major patients by transient elastography (TE) – lack of interference by iron deposition. Br J Hematol 2009;148:476-9
   PubMed Web of Science ®Google Scholar
• Fraquelli M, Cassinerio E, Roghi A, et al. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am J Hematol 2010;85:564-8
   PubMed Web of Science ®Google Scholar
• Musallam KM, Motta I, Salvatori M, et al. Longitudinal changes in serum ferritin correlate with measures of hepatic stiffness in transfusion-independent patients with beta-thalassemia intermedia. Blood Cells Mol Dis 2012;49:136-9
   PubMed Web of Science ®Google Scholar
• Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011;2011:443-50
   PubMed Web of Science ®Google Scholar
• Roghi A, Poggiali E, Pedrotti P, et al. Myocardial and hepatic iron overload assessment by region-based and pixel-wise T2* mapping analysis: technical pitfalls and clinical warnings. J Comput Assist Tomogr 2015;39:128-33
   PubMed Web of Science ®Google Scholar
• Di Marco V, Lo Iacono O, Capra M, et al. α-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia. Hematologica 1992;77:502-6
   PubMed Web of Science ®Google Scholar
• Donohue SM, Wonke B, Hoffbrand AV, et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassemia major. Br J Hematol 1993;83:491-7
   PubMed Web of Science ®Google Scholar
• Clemente MG, Congia M, Lai ME, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994;125:123-8
   PubMed Web of Science ®Google Scholar
• Di Marco V, Lo Iacono O, Almasio P, et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood 1997;90:2207-12
   PubMed Web of Science ®Google Scholar
• Pizzarelli G, Di Gregorio F, Romeo MA, et al. Interferon-alpha therapy in Sicilian and Sardinian polytransfused thalassemic patients with chronic hepatitis C. Biodrugs 1999;12:55-63
   PubMed Web of Science ®Google Scholar
• Spiliopoulou I, Repanti M, Katinakis S, et al. Response to interferon alfa-2b therapy in multitransfused children with beta-thalassemia and chronic hepatitis C. Eur J Clin Microbiol Dis 1999;18:709-15
   PubMed Web of Science ®Google Scholar
• Sievert W, Pianko S, Warner S, et al. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long-term follow-up study in hepatitis C-infected patients with ß thalassemia major. Am J Gastroenterol 2002;97:982-7
   PubMed Web of Science ®Google Scholar
• Artan R, Akcam M, Yilmaz A, Kocacik D. Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J Chemother 2005;6:651-5
   Google Scholar
• Syriopoulou V, Daikos GL, Kostaridou SL, et al. Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Hematologica 2005;90:129-31
   PubMed Web of Science ®Google Scholar
• Vafiadis I, Trilianos P, Vlachogiannakos J, et al. Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit. Ann Hepatol 2013;12:364-70
   PubMedGoogle Scholar
• Telfer PT, Garson JA, Whitby K, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassemic patients. Br J Hematol 1997;98:850-5
   PubMed Web of Science ®Google Scholar
• Li CK, Chan PKS, Ling SC, et al. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassemia major. Br J Hematol 2002;117:755-8
   PubMed Web of Science ®Google Scholar
• Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon α-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Hematologica 2008;93:1247-51
   PubMed Web of Science ®Google Scholar
• Jafroodi M, Asadi R, Heydarzadeh A, Besharati S. Effect of hepatic iron concentration and viral factors in chronic hepatitis C-infected patients with thalassemia major, treated with interferon and ribavirin. Int J Gen Med 2011;4:529-33
   PubMedGoogle Scholar
• Inati A, Taher A, Ghorra S, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassemia major patients with chronic hepatitis C virus infection. Br J Hematol 2005;130:644-6
   PubMed Web of Science ®Google Scholar
• Kalantari H, Rad N. Efficacy of interferon alpha-2b with or without ribavirin in thalassemia major patients with chronic hepatitis C virus infection: a randomized, double blind, controlled, parallel group trial. J Res Med Sci 2010;15:310-16
   PubMed Web of Science ®Google Scholar
• Sood A, Sobti P, Midha V, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol 2010;29:62-5
   PubMedGoogle Scholar
• Di Marco V, Bronte F, Calvaruso V, et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Hematologica 2012;97:679-86
   PubMed Web of Science ®Google Scholar
• Tillman HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010;139:1586-92
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Sarli R, et al. IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassemic HCV-infected patients. Antivir Ther 2011;16:1309-16
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28 polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9
   PubMed Web of Science ®Google Scholar
• Swaim MW, Agarwal S, Rosse WF. Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med 2000;133(9):750-1
   PubMed Web of Science ®Google Scholar
• Ancel DB, Amiot X, Chaslin-Ferbus D, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol 2009;21:726-9
   PubMed Web of Science ®Google Scholar
• Ayyub MA, El-Moursy SA, Khazindar AM, Abbas FA. Successful treatment of chronic hepatitis C virus infection with peginterferonalpha-2a and ribavirin in patients with sickle-cell disease. Saudi Med J 2009;30:712-16
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Mechanisms of antiviral efficacy and failure in chronic hepatitis C. Antiviral Res 2003;59:1-111
   PubMed Web of Science ®Google Scholar
• Chung RT, Gale M, Polyak SJ, et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 2008;47:306-20
   PubMedGoogle Scholar
• Kamal SM, Fouly A, Mohamed S, et al. Peginterferon-alpha2b therapy with and without ribavirin in patients with talassemia: a randomized study. J Hepatol 2006;44(suppl 2):S217
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Hydroxyurea for sickle cell disease. Scientific World J 2002;2:1706-28
   Google Scholar
• Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-51
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004
   PubMed Web of Science ®Google Scholar
• Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive(s)-nucleosides transporters Br J Pharmacol. 1998;123:1587-92
   Google Scholar
• Sulkowski MS. Management of the hematological complications of hepatitis C therapy. Clin Liver Dis 2005;9:601-16
   PubMedGoogle Scholar
• Itoh Y, Okanoue T. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients. J Gastroenterol 2004;39:704-5
   PubMed Web of Science ®Google Scholar
• Ronzoni L, Aghemo A, Rumi MG, et al. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. J Viral Hepat 2014;21:416-23
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone vs deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738-44
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7
   PubMed Web of Science ®Google Scholar
• Degasperi E, Vigano M, Aghemo A, et al. PegIFN-alpha2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Rev Anti Infect Ther 2013;11:459-74
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Aghemo A, Colombo M. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opin Drug Saf 2015;14:473-84
   PubMed Web of Science ®Google Scholar